Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.70 |
| ▸ | MAOA | P21397 | 5/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | SDHA | P31040 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CALML3 | P27482 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 7/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579892 | 1.00 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14898210 | 0.89 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL15861848 | 0.89 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL15861852 | 0.89 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL15861849 | 0.89 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3523143 | 0.89 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL16579897 | 0.88 | MAOB (0.78) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL16579914 | 0.86 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14489968 | 0.86 | MAOB (0.73) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL15861882 | 0.86 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7002020-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050004174-A1 | Antibacterial agents | GORDEEV MIKHAIL F (US) | 2005-01-06 | — | — | US | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | GORDEEV MIKHAIL F (US) | 2002-12-05 | — | — | US | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PAICS, CDK4, OXA1L | MAOB 1298/4885MAOA 1267/4885PTGS1 4238/4885 |
| US-20050004174-A1 | Antibacterial agents | PAICS, OXA1L, PNKP | MAOB 1430/4885MAOA 858/4885PTGS1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.